期刊文献+

Ph^(-)骨髓增殖性肿瘤患者血栓形成的研究进展

Research progress on thrombosis of Philadelphia-negative myeloproliferative neoplasms
原文传递
导出
摘要 Ph-骨髓增殖性肿瘤(MPN)是一种造血干细胞恶性克隆性疾病,表现为一系或多系髓系细胞克隆性增殖。血栓形成是影响MPN患者生存的主要并发症及导致其死亡的原因。影响MPN患者血栓形成的危险因素包括高龄、男性、血栓形成史、白细胞计数增高、血细胞比容(HCT)增高、合并心血管疾病危险因素,以及伴MPN驱动及伴随基因突变等。笔者拟就MPN患者血栓形成的危险因素及机制进行综述,旨在为Ph-MPN患者的血栓防治提供理论依据。 Philadelphia-negative(Ph-)myeloproliferative neoplasms(MPN)is a malignant clonal disease of hematopoietic stem cells,manifested by clonal proliferation of myeloid cells in one or multiple lines.Thrombosis is the main complication affecting survival of patients with MPN which can lead to death.The risk factors affecting thrombosis in MPN patients include aged,male,history of thrombosis,increased white blood cell count and hematocrit(HCT),combined with cardiovascular disease risk factors,and genetic mutations of MPN driver genes and concomitant genes.This paper intends to review these risk factors and mechanisms of thrombosis in patients with MPN,aiming to provide a theoretical basis for the prevention and treatment of thrombosis in patients with Ph-MPN.
作者 高杉 王颖韶 白洁 Gao Shan;Wang Yingshao;Bai Jie(Department of Hematology,Second Hospital of Tianjin Medical University,Tianjin 300211,China)
出处 《国际输血及血液学杂志》 CAS 2022年第3期268-272,共5页 International Journal of Blood Transfusion and Hematology
关键词 骨髓增殖性疾病 真性红细胞增多症 血小板增多 原发性骨髓纤维化 血栓形成 危险因素 Myeloproliferative disorders Polycythemia vera Thrombocythemia Primary myelofibrosis Thrombosis Risk factors
  • 相关文献

二级参考文献20

  • 1Harrison CN, Bareford D, Butt N, et al. Guideline for investiga- tion and management of adults and children presenting with a thrombocytosis [J]. Br J Haematol, 2010, 149 (3):352-375. doi: 10.1111/j.1365-2141.2010.08122.x.
  • 2Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi: 10.1200/ JCO.2010.31.8436.
  • 3Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia [J]. Br J Haematol, 2014, 167 (3): 421-423. doi: 10.1111/bjh.12986.
  • 4Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2015, 26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203.
  • 5Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127 (20):2391-2405. doi: 10.1182/blood-2016-03-643544.
  • 6Besses C, Hemfindez-Boluda JC, Prez Encinas M, et al. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method[J]. Ann Hematol, 2016, 95 (5):719-732. doi: 10.1007/ s00277-016-2614-1.
  • 7Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment[J]. Leukemia, 2008, 22(2):437-438. doi:10.1038/sj. leu.2404914.
  • 8Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification [J]. Am J Hematol, 2010, 85( 1 ):62-69. doi: 10.1002/ajh.21543.
  • 9Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primarymyelofibrosis versus essential thrombocythemia [J]. Leukemia, 2013, 27( 10):1953-1958. doi: 10.1038/leu.2013.74.
  • 10Barosi G. Essential thrombocythemia vs. early/prefibrotic myelo- fibrosis: why does it matter [J]. Best Pract Res Clin Haematol, 2014, 27(2):129-140. doi: 10.1016/j.beha.2014.07.004.

共引文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部